Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls (JCM017)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Chris McCartney, University of Virginia Identifier:
First received: May 17, 2012
Last updated: June 22, 2015
Last verified: June 2015

The purpose of this study is to learn more about how gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) pulses are controlled during puberty. In this study, the investigators aim to discover whether or not giving 2 small doses of progesterone to early pubertal girls will prevent the nighttime increase of GnRH and LH pulses. From the information gathered in this study, the investigators may be able to learn more about how menstrual cycles are normally established in girls during puberty. Ultimately, if these normal processes can be understood, the investigators may be able to better understand abnormalities of puberty.

Condition Intervention
Female Puberty
Drug: Progesterone
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls (JCM017)

Resource links provided by NLM:

Further study details as provided by University of Virginia:

Primary Outcome Measures:
  • LH pulse frequency (number of LH pulses per hour) [ Time Frame: 19 hours [from 1400 hr to 0900 hr] ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: June 2003
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Progesterone
Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
Drug: Progesterone
Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those or = to 42 kg.
Other Name: Progesterone
Placebo Comparator: Placebo
Subjects will take placebo at 1600 h and again at 2000 h.
Drug: Placebo
Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
Other Name: Placebo

  Show Detailed Description


Ages Eligible for Study:   9 Years to 14 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female volunteers in early to mid-puberty (i.e. late Tanner 1 [estradiol level >20 pg/ml], Tanner 2, or Tanner 3)
  • Premenarcheal

Exclusion Criteria:

  • BMI-for-age > 85th percentile or < 5th percentile
  • Pregnancy
  • Inability to comprehend what will be done during the study or why it will done
  • Hyperandrogenism (e.g., hirsutism, elevated free testosterone level)
  • History of allergy to progesterone (which is extremely rare)
  • Hemoglobin less than 12 g/dl and hematocrit less than 36%
  • Persistently abnormal sodium, potassium, or bicarbonate (i.e. confirmed on repeat)
  • Persistently elevated creatinine, hepatic transaminases, or alkaline phosphatase (i.e., confirmed on repeat)
  • Total bilirubin > 1.5 times upper limit of normal (i.e. confirmed on repeat)
  • Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.)
  • Untreated hypo- or hyperthyroidism, reflected by persistently abnormal thyroid-stimulating hormone (TSH) values
  • Premature adrenarche (i.e., occurring before age 8 y)
  • Basal (follicular) 17-hydroxyprogesterone > 200 ng/ml (confirmed on repeat)
  • Dehydroepiandrosterone-sulfate (DHEA-S) > age-appropriate upper limit of normal (confirmed on repeat)
  • Hyperprolactinemia (confirmed on repeat)
  • Weight less than 25 kg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01773772

United States, Virginia
University of Virginia Center for Research in Reproduction
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
Principal Investigator: Christopher R. McCartney, MD University of Virginia
  More Information

No publications provided

Responsible Party: Chris McCartney, Associate Professor, Department of Medicine, Endocrinology and Metabolism, University of Virginia Identifier: NCT01773772     History of Changes
Other Study ID Numbers: 10504, U54HD028934, P50HD028934
Study First Received: May 17, 2012
Last Updated: June 22, 2015
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Progestins processed this record on August 30, 2015